1836 U.S. Patent Office fire

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Retrieved on: 
Wednesday, November 8, 2023
Medical Devices, Health, Hospitals, Surgery, Health Technology, Biotechnology, Chinese patent medicine, Intellectual property, Chinese, 1836 U.S. Patent Office fire, NDRA, Process, Isolation, IP, Microscope

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S. and two in China.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S. and two in China.
  • ENDRA’s intellectual property (IP) portfolio now includes 70 issued patents worldwide, enhancing the IP protection for the novel TAEUS® system.
  • 11806113, titled “Thermoacoustic Probe,” relates to a novel thermoacoustic probe with an optical transducer and an integrated wedge.
  • “These newly issued patents protect and further differentiate ENDRA's thermoacoustic systems in areas of high unmet clinical need, such as the early detection of steatotic liver disease."

Stratus® Medical adds fifth U.S. patent and two Canadian patents to its 29-patent global IP portfolio for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode

Retrieved on: 
Wednesday, November 8, 2023
Patent, Spine, Chronic pain, Physician, Public key certificate, MD, Research, Quality of life, 1836 U.S. Patent Office fire, World Academy of Art and Science, Hospital, Pain, Patient, Interventional pain management, Pharmaceutical industry, Nursing

11,806,070) and first two Canadian patents (Canadian Patent Nos.

Key Points: 
  • 11,806,070) and first two Canadian patents (Canadian Patent Nos.
  • 2,778,997 and 2,799,505) for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode ("NIMBUS").
  • These important patents further protect the Company's valuable NIMBUS intellectual property for its highly differentiated ablation technology for pain.
  • The Company now owns 29 issued patents and 11 pending patent applications for its technology and will continue to submit additional applications.

Mithra’s NEXTSTELLIS® granted additional patent in the United States

Retrieved on: 
Tuesday, November 7, 2023
MITRA, ASX, Patent, Liver, United States Patent and Trademark Office, Tablet, 1836 U.S. Patent Office fire, Pregnancy, CET, Woman, Brussels Stock Exchange, Estetrol, MYX, Pharmaceutical industry, Birth control

Liege, Belgium, 07 November 2023 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that it has been granted an additional patent for NEXTSTELLIS® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United States.

Key Points: 
  • Liege, Belgium, 07 November 2023 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that it has been granted an additional patent for NEXTSTELLIS® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United States.
  • Granted by the United States Patent and Trademark Office, the new patent will provide NEXTSTELLIS® with oral-dosage-unit protection in the US market until 2036.
  • Mithra’s commercialization partner, Mayne Pharma Group Limited (ASX: MYX), holds the license and supply agreement for NEXTSTELLIS®/ESTELLE® in the United States since 2021.
  • David Horn Solomon, CEO of Mithra: “We are excited to have been granted this additional patent coverage for ESTELLE® under the trademark NEXTSTELLIS®, an oral contraceptive with a novel estrogen, in the United States.

Cognos Announces U.S. Patent Award for Cerebral Microdialysis

Retrieved on: 
Monday, November 6, 2023
Ageing, Tau, Patent, CSF, Prevalence, Cell, Cerebrospinal fluid, Traffic barrier, Dialysis, DSM-IV codes, Brain, Multiple sclerosis, Therapy, Microdialysis, 1836 U.S. Patent Office fire, GlobalData, Patient, Medical device, Medical imaging, Pharmaceutical industry, Cognos

We hope that our patent will eventually enable safer and more effective treatment of neurological diseases, such as Alzheimer’s,” said Frank Adell, Chief Executive Officer of Cognos.

Key Points: 
  • We hope that our patent will eventually enable safer and more effective treatment of neurological diseases, such as Alzheimer’s,” said Frank Adell, Chief Executive Officer of Cognos.
  • Cognos intends to develop the patented technology to enable cerebrospinal fluid (“CSF”) dialysis, where CSF is filtered from protein debris.
  • We are excited about the potential impact our technology could have on Alzheimer’s patients and their families,” concluded Mr. Adell.
  • Cognos has an extensive portfolio of patents and patent applications covering all key products, with over 30 exclusively owned patents that cover jurisdictions in the U.S., Canada, Mexico, China, Europe, Australia, and Japan.

Verinext Granted U.S. Patent for IT Infrastructure Automation Methodology

Retrieved on: 
Wednesday, November 1, 2023
1836 U.S. Patent Office fire, Environment, Automation, Invention, Patent, Ecosystem, Logic, Asset management

PHILADELPHIA, Nov. 1, 2023 /PRNewswire/ -- Verinext, the company that delivers transformative business outcomes through technology and services for everything that comes next, today announced that it has been granted a U.S. Patent for its proprietary automation controller for upgrading an IT infrastructure. The proven and patented methodology provides a governance model for automating IT upgrades for minimal downtime and assured security and compliance to mitigate regulatory risk.

Key Points: 
  • PHILADELPHIA, Nov. 1, 2023 /PRNewswire/ -- Verinext , the company that delivers transformative business outcomes through technology and services for everything that comes next, today announced that it has been granted a U.S. Patent for its proprietary automation controller for upgrading an IT infrastructure.
  • Documented as U.S. patent 11,620,122 B2, the Verinext Automation Controller for Upgrading an IT Infrastructure controls the logic and order of operations for enterprise infrastructure updates.
  • Verinext uniquely offers cross-enterprise knowledge, now along with patented methodology, to upgrade, manage and modernize IT infrastructure with precision.
  • The U.S. patent, which was awarded to Verinext and its inventors Gregory L. Tinker and George Carter, was officially filed earlier this year.

VieCure Awarded Patent for Proprietary Capability to Create Personalized Healthcare Treatment Plans for Individuals with Medical Conditions

Retrieved on: 
Tuesday, October 24, 2023
Software, Managed Care, Oncology, General Health, Health, Artificial Intelligence, Health Technology, Technology, Element, 1836 U.S. Patent Office fire, Standard of care, Cancer, AI, Medicine, Patent, Patient, Pharmaceutical industry, Medical imaging, Health insurance, Medical device

Today VieCure announced that the United States Patent & Trademark Office has issued VieCure’s patent, U.S. Patent No.

Key Points: 
  • Today VieCure announced that the United States Patent & Trademark Office has issued VieCure’s patent, U.S. Patent No.
  • 11,798,689 “Generating Customizable Personal Healthcare Treatment Plans”, covering the VieCure platform’s ability to use data and apply computerized algorithms to create healthcare treatment plans that are individualized for each patient’s unique circumstances.
  • This patent is not limited to oncology but rather encompasses personalized healthcare treatment plans for all medical conditions.
  • The patient data is then used to generate personalized treatment plans, which can be updated automatically over time.

Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2 Gene Therapy

Retrieved on: 
Wednesday, October 25, 2023
Survival, Ageing, Patent, Therapy, AMD, Pancreas, Liver, Entrepreneurship, Cell, Tissue, Methylation, Research and development, Brain, 1836 U.S. Patent Office fire, Retina, SAN, Fine chemical, Pharmaceutical industry, Research

SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,793,890, entitled "ELOVL2 Constructs for Human Gene Therapy". The patent, which is exclusively owned by Visgenx, has an expiration date of October 19, 2041.   

Key Points: 
  • 11,793,890, entitled "ELOVL2 Constructs for Human Gene Therapy".
  • The patent, which is exclusively owned by Visgenx, has an expiration date of October 19, 2041.
  • Accordingly, we believe that ELOVL2 gene therapy is an attractive strategy for treating these conditions."
  • "The issued patent covers an optimized ELOVL2 transgene that can be used in expression vectors targeting multiple tissues," said Chris Chavez, Ph.D., Vice President of Research and Development at Visgenx and primary inventor on the patent.

Sports Data Labs, Inc. Announces Issuance of New U.S. Patent which Expands Scope for Health Drone

Retrieved on: 
Tuesday, October 10, 2023
Data Management, Consumer Electronics, Technology, Research, Sports, Other Defense, Data Analytics, Aerospace, Manufacturing, Mobile, Wireless, General Sports, Defense, Satellite, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Software, Health, Hardware, Science, AI, Multimedia, Patent, Animal, United States Patent and Trademark Office, Sport, Human, 1836 U.S. Patent Office fire, Invention, Intelligence, UAV

Sports Data Labs, Inc. (SD Labs), an award-winning leader in AI-based technology solutions, announced today that the United States Patent and Trademark Office has issued the company U.S. Patent No.

Key Points: 
  • Sports Data Labs, Inc. (SD Labs), an award-winning leader in AI-based technology solutions, announced today that the United States Patent and Trademark Office has issued the company U.S. Patent No.
  • 11,778,987 which expands its coverage for its novel unmanned aerial vehicle (UAV)-based system related to collecting, analyzing, distributing, and monitoring biological sensor data from humans and other animals.
  • “We are thrilled with the continued expansion of our IP Portfolio,” said Vivek Khare, Co-Founder & Chief Technology Officer of SD Labs.
  • “This increased scope enables significantly broader reach for our novel inventions and allows us to explore broader applications in health monitoring with our partners.”

TETROUS, INC. ANNOUNCES ISSUE OF AN ADDITIONAL U.S. PATENT RELATED TO ENFIX™ DEMINERALIZED BONE FIBER IMPLANTS FOR SPORTS MEDICINE SURGICAL PROCEDURES

Retrieved on: 
Thursday, October 5, 2023
Patent, United States Patent and Trademark Office, Doctor of Philosophy, DBF, 1836 U.S. Patent Office fire, Failure, Anterior cruciate ligament, ACL, 3D printing

EnFix RC™, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair.

Key Points: 
  • EnFix RC™, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair.
  • The newly issued patent, titled "Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair", further augments Tetrous' strong portfolio of intellectual property covering demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair.
  • "We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent.
  • "Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the next-generation enthesis repair market".

Meati Foods™ Receives U.S. Patent for MushroomRoot™ (Neurospora crassa) Food Applications

Retrieved on: 
Wednesday, October 4, 2023
Organic Food, Retail, Environment, Sustainability, Supermarket, Food, Beverage, Sprouts, 1836 U.S. Patent Office fire, Whole Foods Market, Patent, Powder, Mycelium, Nutrient, Seafood, Research, PIPA, UC Davis Department of Viticulture and Enology, Cardiovascular disease, Mr. Meaty, Death, United States Patent and Trademark Office, LEAP, UC, PDCAAS, AI, Malnutrition, Neurospora crassa, Health, Dietary supplement, Meijer

In collaboration with PIPA, Meati™ also completed a swift, AI-driven study on MushroomRoot’s health benefits.

Key Points: 
  • In collaboration with PIPA, Meati™ also completed a swift, AI-driven study on MushroomRoot’s health benefits.
  • An additional set of rare compounds was identified that could yield even more pointed health benefits.
  • “The patent is a culmination of our years-long journey to have our foundational work with MushroomRoot and its wide-ranging food applications acknowledged and protected,” said Justin Whiteley, Meati co-founder and chief science officer.
  • 11,751,596 to Meati Foods on September 12, 2023, ensuring exclusivity over Meati’s N. crassa-based inventions until 2039.